Interview with Emily Cheah, General Manager, BRASS
Biomedical Research and Support Services Pte Ltd. is an NUS University spin-off that has been around for more than 14 years; last year the company name was changed to BRASS.…
Address: 33 Ubi Avenue 3,
#06-13/14 Vertex,
Singapore 408868.
33 Ubi Avenue 3, #06-13/14 Vertex, Singapore 408868.
33 Ubi Avenue 3, #06-13/14 Vertex, Singapore 408868.
33 Ubi Avenue 3, #06-13/14 Vertex,,Singapore
Tel: +65 6742 6007
Web: http://www.brass-asiapacific.com/c/
BRASS™ was conceived in the National University of Singapore (NUS) on May 1996 with the primary aim of supporting medical device development from concept into reality.
The brainchild of Assoc. Prof. Eugene Khor, BRASS™ is the answer to the biomedical industry’s need for vital infrastructure in support of the medical devices industry. BRASS™ was registered in December 1997 (hence “SINCE 1997”) and in April 1, 1999, the NUS incubation component of BRASS was granted permission to spin-off as a separate entity.
BRASS™ was awarded sole distributorship for the Charles River Endosafe brand of LAL Bacterial Endotoxin Test reagents in Singapore, Indonesia and Malaysia, an achievement that still remains to this day. With its growing success, BRASS™ was able to secure a partnership with the North American Science Associates, Inc. (NAMSA), the world leader in medical device safety evaluation, in July 2002. With this strategic alliance, BRASS™ is able to provide the full panel of GLP ISO 10993 biocompatibility testing, functional and performance studies, and material characterization to the medical device industry as well as gained the rights to distribute the full series of NAMSA Sterilization Assurance Products in several territories in the Asia Pacific region. In 2011, BRASS™ successfully attained representation for Charles River Biopharmaceutical Services in Singapore, Malaysia, Indonesia and Vietnam.
Thirteen years since its humble beginnings, BRASS™ has grown from strength to strength, and counts as its clients various multinational industry leaders, innovative start-ups and research institutes from the pharmaceutical and medical device industry in South East Asia.
Quality Product Provider: broad range of high quality and reliable media, packaging and sterilization assurance products.
Medical Device Expertise
Specialist in Microbiological Testing
Strategic and customized solutions for product development, regulatory compliance and quality assurance throughout the entire life-cycle of the medical device.
Biomedical Research and Support Services Pte Ltd. is an NUS University spin-off that has been around for more than 14 years; last year the company name was changed to BRASS.…
Charles Stacey, President and CEO of Cerecin, discusses the company’s strategic direction and partnerships as it advances its Alzheimer’s treatment into Phase 3 trials. He highlights the importance of collaboration…
Thanks to its strategic location and pro-business environment, Singapore has established itself as a major pharma manufacturing hub in the Asia-Pacific region. Five Big Pharma companies have stepped up their…
Writing in the November 2024 edition of DIA’s Global Forum magazine, Johnson & Johnson’s Sandy Chan looks at the fast-evolving regulatory framework for medicines in the dynamic Asia-Pacific region. …
A run-through of some of the most striking recent stories from pharma in the dynamic Asia-Pacific region, including Japan’s attempts to bring back Big Pharma investment; UCB’s decision to divest…
A roundup of some of the most important recent pharma news from the dynamic ASEAN region, including a big new investment from Novartis in its antibody plant in Singapore, the…
The latest pharma news from Singapore, including J&J Innovation’s continued investment in Singapore; Evotec’s new Singaporean venture, 65LAB; BeiGene’s cancer drug approval in the country; Novo Nordisk’s acquisition of local…
As the COVID-19 pandemic showed, vaccination is perhaps the most important tool a country has in maintaining the health of its population. Writing in the May 2023 edition of DIA’s…
The latest pharma and healthcare news from Southeast Asia, including the partnership between KPJ Healthcare and Samsung; Specialised Therapeutics’ immuno-oncology therapy; Singapore biotech CytoMed Therapeutics’ IPO, the Malaysian approval of…
The latest pharma and healthcare news from Southeast Asia, including the proposed healthcare programs of Thailand’s political parties for the upcoming election; Singapore’s approval of Pfizer’s 20-valent pneumococcal conjugate vaccine;…
The biggest pharma stories from Southeast Asia, including GSK’s new HPF manufacturing investment, license suspensions for Samco Farma and Ciubros Farma after Indonesia’s acute kidney injury crisis, Kalbe’s Aventis share…
MSD is set to inject an additional USD 500 million into its existing Singapore manufacturing operations with two new facilities to produce vaccines and biologics. One of the new plants…
On World Heart Day 2022 Iris Zemzoum of Novartis Asia Pacific, Middle East & Africa (APMA) outlines the devastating impact of cardiovascular disease (CVD) as well as Novartis’ multipronged approach…
See our Cookie Privacy Policy Here
